EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis

Mohammad Al Hayek, Bisher Sawaf, Mohammed S Beshr, Ahmad Kassem, Dahham Alsoud, Mulham Alom, Rana H Shembesh, Abdelaziz H Salama, Yusuf Hallak, Shahem Abbarh, Elias Batikh, Mosa Shibani und 3 weitere

Inflammatory Intestinal Diseases · 30.07.2025 · 10 (1) · 265-284

DOI: 10.1159/000547707 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 30.07.2025. Verfasst von Mohammad Al Hayek und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn’s disease (CD), but comparative data between agents remain limited. This study aimed to assess and rank the efficacy of IL-12/23 and IL-23 inhibitors across key clinical and endoscopic outcomes using network meta-analysis.

Methods

We included randomized controlled trials (RCTs) evaluating IL-12/23 (ustekinumab) and IL-23 inhibitors (risankizumab, mirikizumab, guselkumab, briakinumab, and MEDI2070) versus placebo or each other in adult patients with moderate-to-severe CD. Primary outcomes included clinical and endoscopic remission (assessed at the end of the induction and maintenance phases) and corticosteroid-free clinical remission (assessed at the end of the maintenance phase). Risk ratios (RRs) were estimated using a random-effects model. All analyses were conducted in R using the netmeta package. Surface under the cumulative ranking curve (SUCRA) analysis was used to rank treatments across these endpoints.

Results

Fourteen RCTs involving 4,464 patients during the induction phase and 2,601 patients during the maintenance phase were included. Guselkumab achieved the highest clinical remission rate compared to placebo at the end of both the induction phase (RR = 2.62; 95% confidence interval [CI], 2.03–3.39; SUCRA: 91%) and the maintenance phase (RR = 2.37; 95% CI, 1.64–3.42; SUCRA: 85%). In addition, guselkumab was superior to mirikizumab in terms of clinical remission at the end of the induction phase (RR = 1.66; 95% CI, 1.16–2.37). Guselkumab was also the most effective agent for achieving corticosteroid-free clinical remission compared to placebo (RR = 3.06; 95% CI, 1.52–6.16; SUCRA: 78%) at the end of the maintenance phase. Mirikizumab achieved the highest endoscopic remission rate compared to placebo at the end of both the induction phase (RR = 3.52; 95% CI, 1.50–8.27; SUCRA: 78%) and the maintenance phase (RR = 5.84; 95% CI, 2.76–12.37; SUCRA: 88%). Furthermore, mirikizumab, guselkumab, and risankizumab were superior to ustekinumab in terms of endoscopic remission at the end of the maintenance phase.

Conclusions

These findings suggest that guselkumab may be a potential first-line therapy for patients presenting with predominant clinical symptoms, offering the additional benefit of reducing corticosteroid use and its associated long-term risks. Conversely, mirikizumab may be the preferred option for patients with persistent mucosal inflammation, owing to its superior efficacy in achieving endoscopic remission.

Schlagwörter

Stichwörter der Autor:innen

Corticosteroid-free remissionCrohn’s diseaseEndoscopic remissionIL-12/23 inhibitorsIL-23 inhibitorsNetwork meta-analysis

Autor:innen und Institutionen

  • Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
  • Internal Medicine, University of Toledo, Toledo, OH, USA.
  • Sana'a University, Faculty of Medicine and Health Sciences, Sana'a, Yemen.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Internal Medicine, Southern Illinois University School of Medicine, Chicago, IL, USA.

Zitieren

APA

Al Hayek, M., Sawaf, B., Beshr, M. S., Kassem, A., Alsoud, D., Alom, M., Shembesh, R. H., Salama, A. H., Hallak, Y., Abbarh, S., Batikh, E., Shibani, M., Elhadi, M., Afzali, A., & Regueiro, M. (2025). Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Inflammatory Intestinal Diseases, 10(1), 265-284. https://doi.org/10.1159/000547707

Vancouver

Al Hayek M, Sawaf B, Beshr MS, Kassem A, Alsoud D, Alom M, et al. Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Inflammatory Intestinal Diseases. 2025;10(1):265-284. doi:10.1159/000547707

BibTeX
@article{AlHayek2025,
  author = {Al Hayek, Mohammad and Sawaf, Bisher and Beshr, Mohammed S and Kassem, Ahmad and Alsoud, Dahham and Alom, Mulham and Shembesh, Rana H and Salama, Abdelaziz H and Hallak, Yusuf and Abbarh, Shahem and Batikh, Elias and Shibani, Mosa and Elhadi, Muhammed and Afzali, Anita and Regueiro, Miguel},
  title = {Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis},
  journal = {Inflammatory Intestinal Diseases},
  year = {2025},
  volume = {10},
  number = {1},
  pages = {265--284},
  doi = {10.1159/000547707}
}
Kostenlos starten →